and Human Services (HHS)
EXPIRED
Participating Organization(s) |
National Institutes of Health (NIH) |
National Institute on Aging (NIA) |
|
Funding Opportunity Title |
Pain in Aging (R21) |
Activity Code |
R21 Exploratory/Developmental Research Grant Award |
Announcement Type |
Reissue of PA-09-194. |
Related Notices
|
|
Funding Opportunity Announcement (FOA) Number |
PA-13-059 |
Companion Funding Opportunity |
TPA-13-219, PA-13-058, R01 Research Project Grant |
Catalog of Federal Domestic Assistance (CFDA) Number(s) |
93.866, 93.273, 93.279 |
Funding Opportunity Purpose |
This FOA encourages Exploratory/Developmental Research Grant (R21) applications from institutions/organizations that propose to study pain from an aging perspective, including studies of older populations, studies of age differences and age-related changes in pain processes and experiences, and studies of pain treatment and management in older adults. This FOA particularly encourages studies on 1) mechanisms and predictors of pain experience in aging, 2) development and evaluation of pain assessment tools for older adults or older model organisms, and 3) development and evaluation of pain management strategies in older adults, with particular attention to the challenges associated with treating pain in patients with multiple morbidities. Studies may address a variety of approaches and outcomes including biological (i.e., genetic, molecular, neurobiological), clinical, behavioral, psychological, and social factors. Both animal models (especially aged animals) and human subjects are appropriate for this FOA. |
Posted Date |
December 20, 2012 |
Open Date (Earliest Submission Date) |
January 16, 2013 |
Letter of Intent Due Date(s) |
Not Applicable |
Application Due Date(s) |
Standard dates apply by 5:00 PM local time of applicant organization. |
AIDS Application Due Date(s) |
Standard AIDS dates apply, by 5:00 PM local time of applicant organization. |
Scientific Merit Review |
Standard dates apply |
Advisory Council Review |
Standard dates apply |
Earliest Start Date |
Standard dates apply |
Expiration Date |
January 8, 2016 |
Due Dates for E.O. 12372 |
Not Applicable |
Required Application Instructions
It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide, except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts). Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.
Part 1. Overview Information
Part 2. Full Text of the Announcement
Section I. Funding Opportunity Description
Section II. Award Information
Section III. Eligibility Information
Section IV. Application and Submission
Information
Section V. Application Review Information
Section VI. Award Administration Information
Section VII. Agency Contacts
Section VIII. Other Information
Pain is one of the most frequently reported and costly symptoms in clinical settings, and has often been called the fifth vital sign. According to the Institute of Medicine’s recent report, Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research, over 100 million Americans suffer from chronic pain conditions. This figure is greater than the number of individuals with diabetes, heart disease, stroke, and cancer combined. Annual health care costs attributable to pain are conservatively estimated at over half of a trillion dollars.
The prevalence of pain has been increasing across all adult age groups, but is consistently greatest among Americans aged 65 and older. This segment of the population also has the highest long-term consumption rate of medications for pain (1). The prevalence of age-related diseases associated with chronic pain, such as arthritis, diabetes, and cancer, is expected to rise even further due to the aging of the US population. As such, we will likely see substantially increased demand for effective pain care in older adults into the foreseeable future.
Assessment and treatment of pain may involve a broad array of pharmacologic and non-pharmacologic interventions, a variety of care providers, and multiple care settings. With older individuals, the complexity of these factors is often compounded by aging-related issues such as age-related changes in related neural systems, multiple co-occurring diseases and conditions (multiple morbidity), multiple concurrent medications (polypharmacy), alterations in drug absorption and metabolism, impaired cognitive capacity, impaired functional capacity, and increased barriers to care. Studies looking at the effectiveness of opioids, which are the most commonly used medications for treating different types of chronic pain, as well as the risks of adverse effects stemming from the factors noted above, as well as the risks of tolerance, dependence, and addiction would be of interest. Moreover, treatment of pain in older adults frequently involves trade-offs among multiple competing risks and benefits, but there is scant evidence for weighing these factors effectively. Studies in older cohorts may be further challenged by physiologic heterogeneity, a quintessential characteristic of older adult populations. Although a variety of clinical practice guidelines for pain have been published, including those specifically for older adults (2), the evidence base underlying these guidelines would benefit from further research. In particular, understanding how differences in patient-, provider-, and system-level factors affect treatment outcomes is largely lacking.
In order to address some of these knowledge gaps and practice barriers, the National Institute on Aging (NIA) has led several initiatives aimed at identifying and supporting key research opportunities on pain and aging. In collaboration with the NIH Pain Consortium, the NIA sponsored an exploratory workshop entitled Mechanisms and Management of Pain in the Elderly in 2008 (see Meeting Agenda and Executive Summary). The following year, a series of program announcements focusing on pain in aging were issued (PA-09-193, PA-09-194, and PA-09-195). In 2010, NIA, under the aegis of the NIH Pain Consortium, convened an Expert Panel Discussion on Pharmacological Management of Chronic Pain in Older Adults (see Meeting Agenda and Executive Summary). A summary of the meeting, which detailed the identified research gaps and methods to address them, was published in Pain Medicine (1). In 2011, NIA issued RFA-AG-12-006, which solicited studies using existing data to evaluate the safety or effectiveness of pharmacological treatments for chronic pain in older adults. The NIA now offers this reissuance of the 2009 Program Announcement to continue its support of research on key research topics in pain from an aging perspective.
One particularly promising area of research may lie at the intersection of genetics and the neurobiology of pain. Over 130 genes have been identified that are putatively associated with pain processing, pain experience, or interactions with pain treatments. Neuroimaging studies have identified brain regions critical for processing pain information and regulating pain experiences. Collectively, these approaches may lead to enhanced strategies for diagnosis and treatment, which may benefit cognitively impaired individuals in particular, and may also advance the vision of more personalized pain management in general.
The extent to which normal age-related changes in cognitive or emotional function impact pain experiences and pain coping/management is understudied, as is the extent to which approaches to pain management impact normal psychological function in older adults. In addition, research aimed at understanding health disparities (e.g. gender, racial/ethnic, socioeconomic) in the progression and severity of pain at older ages and in trajectories of treatment, outcomes, and behavioral adaptations to painful conditions among different subpopulations of older adults is needed.
The increasing availability of large-scale population-based survey data on painful conditions and disability among older populations in both the US and internationally also opens opportunities for comparative analyses of prevalence and severity of pain regionally and cross-nationally, and investigation of the causes of regional and national differences in pain experience and treatment.
This FOA encourages a broad range of applications examining the mechanisms and processes by which factors at all levels of analysis (from molecular to social/institutional) impact the experience, representation, processing, management, and treatment of pain in older adults. Both basic and translational research is encouraged under this FOA. Applications at a single level of analysis are welcomed (e.g. studies of neural circuitry for pain processing in aging), as are studies examining processes across levels of analysis. Studies focused on normal age differences and age-related changes in pain processes, as well as on age-related diseases or disorders, including pain in older adults with comorbid conditions or with Alzheimer’s disease or other age-related dementias, are strongly encouraged. New pain assessment methods and management approaches targeting older adults are also encouraged. Both human and animal model studies are appropriate. This FOA encompasses the range of scientific approaches, including genetic, molecular, imaging, physiological, clinical, behavioral, social, psychological, comparative effectiveness research (CER), and epidemiological (including cross-national comparative) approaches.
An association between chronic pain conditions and alcohol dependence has been suggested in numerous studies with episodes of alcohol abuse antedating chronic pain in some and alcohol dependence emerging after the onset of chronic pain in others. However, the interaction between alcohol use and pain in older people has not been investigated. While acute alcohol may be analgesic, the long-term alcohol use in chronic pain conditions in older population may worsen pain and exacerbate associated anxiety and depressive-like conditions. The effects of chronic use of alcohol on neuroimmune systems may play a crucial role in determining the pain sensitivity and treatment outcome in elderly. NIAAA is interested in receiving applications addressing neuronal and glial mechanisms related to alcohol and chronic pain in older populations.
Because of the complexities of both aging processes and pain mechanisms, applications are encouraged to incorporate multidisciplinary approaches whenever appropriate to the study. Expertise may be integrated among multiple relevant disciplines including, but not limited to, anesthesiology, neurology, geriatrics, psychology and/or neuropsychology, neuroscience, economics, demography, epidemiology, sociology, pharmacology and/or neuropharmacology, nursing, physical medical & rehabilitation, and physical and/or occupational therapy.
Comparisons between older and younger subjects are encouraged in either animal or human studies. No individual ranges for older or elderly are specified for this FOA; rather, the demarcation between older and younger subjects should be dependent on the research hypotheses and subjects under study. Furthermore, investigators are encouraged to study a broad range of midlife and older subjects, from early to advanced old age.
Applicants can find a compilation of aging-relevant population studies at http://nihlibrary.ors.nih.gov/nia/ps/niadb.asp. Information about NIA-supported aged animal colonies and other scientific resources can be found at http://www.nia.nih.gov/research/scientific-resources.
Applicants are encouraged to use self-reported measures of pain, function, affect, or other relevant domains where appropriate, such as the Patient-Reported Outcomes Medical Information System (PROMIS), and/or objective and self-report measures of cognitive, emotional, sensory, or motor function such as the NIH Toolbox for Assessment of Neurological and Behavioral Function (NIH Toolbox). Both PROMIS and the NIH Toolbox can also be found, along with other potentially suitable assessment tools, at www.assessmentcenter.net.
(1) Reid MC, Bennett DA, Chen WG, Eldadah BA, et al. Improving the Pharmacologic Management of Pain in Older Adults: Identifying the Research Gaps and Methods to Address Them. Pain Medicine, 2011; 12(9):1336-1357.
(2) American Geriatrics Society Panel on the Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons: American Geriatrics Society. Journal of the American Geriatrics Society, 2009; 57:1331-1346.
Funding Instrument |
Grant: A support mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity. |
Application Types Allowed |
New The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types. |
Funds Available and Anticipated Number of Awards |
The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. |
Award Budget |
Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year. |
Award Project Period |
The total project period for an application submitted in response to this funding opportunity may not exceed two years. |
NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made in response to this FOA.
Higher Education Institutions
The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:
Nonprofits Other Than Institutions of Higher Education
For-Profit Organizations
Governments
Other
Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Foreign components, as defined in
the NIH Grants Policy Statement, are allowed.
Applicant organizations must complete the following registrations as described in the SF424 (R&R) Application Guide to be eligible to apply for or receive an award. Applicants must have a valid Dun and Bradstreet Universal Numbering System (DUNS) number in order to begin each of the following registrations.
All Program Directors/Principal Investigators (PD(s)/PI(s))
must also work with their institutional officials to register with the eRA
Commons or ensure their existing eRA Commons account is affiliated with the eRA
Commons account of the applicant organization.
All registrations must be completed by the application due date. Applicant
organizations are strongly encouraged to start the registration process at
least 6 weeks prior to the application due date.
Any individual(s) with the skills, knowledge, and resources
necessary to carry out the proposed research as the Program Director(s)/Principal
Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to
develop an application for support. Individuals from underrepresented racial
and ethnic groups as well as individuals with disabilities are always encouraged
to apply for NIH support.
For institutions/organizations proposing multiple PDs/PIs, visit the Multiple
Program Director/Principal Investigator Policy and submission details in the Senior/Key
Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.
This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.
Applicant organizations may submit more than one application, provided that each application is scientifically distinct.
NIH will not accept any application that is essentially the same as one already reviewed within the past thirty-seven months (as described in the NIH Grants Policy Statement), except for submission:
Applicants must download the SF424 (R&R) application package associated with this funding opportunity using the Apply for Grant Electronically button in this FOA or following the directions provided at Grants.gov.
It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide, except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
For information on Application Submission and Receipt, visit Frequently Asked Questions Application Guide, Electronic Submission of Grant Applications.
The forms package associated with this FOA includes all applicable components, mandatory and optional. Please note that some components marked optional in the application package are required for submission of applications for this FOA. Follow all instructions in the SF424 (R&R) Application Guide to ensure you complete all appropriate optional components.
All page limitations described in the SF424 Application Guide and the Table of Page Limits must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:
Resource Sharing Plan
Individuals are required to comply with the instructions for the Resource Sharing Plans (Data Sharing Plan, Sharing Model Organisms, and Genome Wide Association Studies (GWAS)) as provided in the SF424 (R&R) Application Guide.
Appendix
Do not use the Appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.
Foreign (non-U.S.) institutions must follow policies described in the NIH Grants Policy Statement, and procedures for foreign institutions described throughout the SF424 (R&R) Application Guide.
Part I. Overview Information contains information about Key Dates. Applicants are encouraged to submit applications before the deadline to ensure they have time to make any application corrections that might be necessary for successful submission.
Organizations must submit applications via Grants.gov, the online portal to find and apply for grants across all Federal agencies. Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH’s electronic system for grants administration.
Applicants are responsible for viewing their application before the deadline in the eRA Commons to ensure accurate and successful submission.
Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.
This initiative is not subject to intergovernmental review.
All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Pre-award costs are allowable only as described in the NIH Grants Policy Statement.
Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide. Paper applications will not be accepted.
Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.
For assistance with your electronic application or for more information on the electronic submission process, visit Applying Electronically.
Important
reminders:
All PD(s)/PI(s) must include their eRA Commons ID in the
Credential field of the Senior/Key Person Profile Component of the
SF424(R&R) Application Package. Failure to register in the Commons
and to include a valid PD/PI Commons ID in the credential field will prevent
the successful submission of an electronic application to NIH.
The applicant organization must ensure that the DUNS number it provides on the
application is the same number used in the organization’s profile in the eRA
Commons and for the System for Award Management (SAM). Additional information
may be found in the SF424 (R&R) Application Guide.
See more
tips for avoiding common errors.
Upon receipt, applications will be evaluated for completeness by the Center for Scientific Review, NIH. Applications that are incomplete will not be reviewed.
Applicants are required to follow the instructions for post-submission materials, as described in NOT-OD-10-115.
Only the review criteria described below will be considered in the review process. As part of the NIH mission, all applications submitted to the NIH in support of biomedical and behavioral research are evaluated for scientific and technical merit through the NIH peer review system.
For this particular announcement, note the following:
The R21 exploratory/developmental grant supports investigation of novel scientific ideas or new model systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research. An R21 grant application need not have extensive background material or preliminary information. Accordingly, reviewers will focus their evaluation on the conceptual framework, the level of innovation, and the potential to significantly advance our knowledge or understanding. Appropriate justification for the proposed work can be provided through literature citations, data from other sources, or, when available, from investigator-generated data. Preliminary data are not required for R21 applications; however, they may be included if available.
Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).
Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.
Significance
Does the project address an important problem or a critical barrier to progress in the field? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?
Investigator(s)
Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or New Investigators, or in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?
Innovation
Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?
Approach
Are the overall strategy, methodology, and analyses
well-reasoned and appropriate to accomplish the specific aims of the project?
Are potential problems, alternative strategies, and benchmarks for success
presented? If the project is in the early stages of development, will the
strategy establish feasibility and will particularly risky aspects be managed?
If the project involves clinical research, are the plans for 1) protection of
human subjects from research risks, and 2) inclusion of minorities and members
of both sexes/genders, as well as the inclusion of children, justified in terms
of the scientific goals and research strategy proposed?
Environment
Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?
As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.
Protections for Human Subjects
For research that involves human subjects but does
not involve one of the six categories of research that are exempt under 45 CFR
Part 46, the committee will evaluate the justification for involvement of human
subjects and the proposed protections from research risk relating to their
participation according to the following five review criteria: 1) risk to
subjects, 2) adequacy of protection against risks, 3) potential benefits to the
subjects and others, 4) importance of the knowledge to be gained, and 5) data
and safety monitoring for clinical trials.
For research that involves human subjects and meets the criteria for one or
more of the six categories of research that are exempt under 45 CFR Part 46,
the committee will evaluate: 1) the justification for the exemption, 2) human
subjects involvement and characteristics, and 3) sources of materials. For
additional information on review of the Human Subjects section, please refer to
the Human
Subjects Protection and Inclusion Guidelines.
Inclusion of Women, Minorities, and Children
When the proposed project involves clinical research, the committee will evaluate the proposed plans for inclusion of minorities and members of both genders, as well as the inclusion of children. For additional information on review of the Inclusion section, please refer to the Human Subjects Protection and Inclusion Guidelines.
Vertebrate Animals
The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following five points: 1) proposed use of the animals, and species, strains, ages, sex, and numbers to be used; 2) justifications for the use of animals and for the appropriateness of the species and numbers proposed; 3) adequacy of veterinary care; 4) procedures for limiting discomfort, distress, pain and injury to that which is unavoidable in the conduct of scientifically sound research including the use of analgesic, anesthetic, and tranquilizing drugs and/or comfortable restraining devices; and 5) methods of euthanasia and reason for selection if not consistent with the AVMA Guidelines on Euthanasia. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.
Biohazards
Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.
Resubmissions
For Resubmissions, the committee will evaluate the application as now presented, taking into consideration the responses to comments from the previous scientific review group and changes made to the project.
Renewals
Not Applicable
Revisions
Not Applicable
As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.
Applications from Foreign Organizations
Reviewers will assess whether the project presents special opportunities for furthering research programs through the use of unusual talent, resources, populations, or environmental conditions that exist in other countries and either are not readily available in the United States or augment existing U.S. resources.
Select Agent Research
Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).
Resource Sharing Plans
Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: 1) Data Sharing Plan; 2) Sharing Model Organisms; and 3) Genome Wide Association Studies (GWAS).
Budget and Period of Support
Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.
Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s), in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.
As part of the scientific peer review, all applications:
Applications will be assigned on the basis of established PHS referral guidelines to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications. Following initial peer review, recommended applications will receive a second level of review by the appropriate national Advisory Council or Board. The following will be considered in making funding decisions:
After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons.
Information regarding the disposition of applications is available in the NIH Grants Policy Statement.
If the application is under consideration for funding, NIH
will request "just-in-time" information from the applicant as
described in the NIH Grants
Policy Statement.
A formal notification in the form of a Notice of Award (NoA) will be provided
to the applicant organization for successful applications. The NoA signed by
the grants management officer is the authorizing document and will be sent via
email to the grantee’s business official.
Awardees must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection
of an application for award is not an authorization to begin performance. Any
costs incurred before receipt of the NoA are at the recipient's risk. These
costs may be reimbursed only to the extent considered allowable pre-award costs.
Any application awarded in response to this FOA will be subject to the DUNS, SAM
Registration, and Transparency Act requirements as noted on the Award
Conditions and Information for NIH Grants website.
All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities. More information is provided at Award Conditions and Information for NIH Grants.
Cooperative Agreement Terms and Conditions of Award
Not Applicable
When multiple years are involved, awardees will be required to submit the annual Non-Competing Progress Report (PHS 2590 or RPPR) and financial statements as required in the NIH Grants Policy Statement.
A final progress report, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement.
The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All awardees of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000. See the NIH Grants Policy Statement for additional information on this reporting requirement.
We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.
Grants.gov
Customer Support (Questions regarding Grants.gov registration and
submission, downloading or navigating forms)
Contact Center Phone: 800-518-4726
Email: support@grants.gov
GrantsInfo (Questions regarding application instructions and
process, finding NIH grant resources)
Telephone 301-710-0267
TTY 301-451-5936
Email: GrantsInfo@nih.gov
eRA Service Desk (Questions regarding ASSIST, eRA Commons registration, tracking application status, post submission issues)
Phone: 301-402-7469 or 866-504-9552 (Toll Free)
TTY: 301-451-5939
Email: commons@od.nih.gov
Direct general inquiries, as well as questions pertaining to neurobiological, neurobehavioral, neuropsychological, or neuroepidemiological approaches, or neural mechanism-based assessment, therapeutic and clinical studies to:
Wen G. Chen, Ph.D.
National Institute on Aging (NIA)
Telephone: (301) 496-9350
Email: chenw@nia.nih.gov
Direct questions pertaining to pain management related to medical conditions common in older adults, management algorithms for older complex patients, physical function or medical outcomes, and other related geriatric issues to:
Basil Eldadah, M.D., Ph.D.
National Institute on Aging (NIA)
Phone: (301) 496-6761
Email: eldadahb@nia.nih.gov
Direct questions pertaining to racial, ethnic and socioeconomic disparities in pain; development of pain measures for population-based samples; and research addressing psychological, behavioral, or social mechanisms and processes involved in pain experience (including integrative science approaches) to:
Lisbeth Nielsen, Ph.D.
National Institute on Aging (NIA)
Phone: (301) 402-4156
Email: nielsenli@nia.nih.gov
Dave Thomas, Ph.D.
National Institute on Drug Abuse (NIDA)
Phone: (301) 435-1313
Email: dthomas1@nida.nih.gov
Soundar Regunathan, Ph.D.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Phone: (301) 443-1192
Email: soundar.regunathan@nih.gov
Examine your eRA Commons account for review assignment and contact information (information appears two weeks after the submission due date).
Robin Laney
National Institute on Aging (NIA)
Telephone: (301) 496-1473
Email: Robin.Laney@mail.nih.gov
Christine Kidd
National Institute on Drug Abuse (NIDA)
Telephone: (301) 435-1372
Email: ckidd@nida.nih.gov
Judy S. Fox
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Telephone: (301) 443-4704
Email: jfox@mail.nih.gov
Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Parts 74 and 92.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
|
| ||||||
|
|
|
Department of Health and Human Services (HHS) |
|
|||
|
NIH... Turning Discovery Into Health® |
||||||